Compare WINA & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WINA | GENB |
|---|---|---|
| Founded | 1988 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2006 | N/A |
| Metric | WINA | GENB |
|---|---|---|
| Price | $384.45 | $12.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $23.20 |
| AVG Volume (30 Days) | 69.0K | ★ 315.9K |
| Earning Date | 04-15-2026 | 05-03-2026 |
| Dividend Yield | ★ 3.55% | N/A |
| EPS Growth | ★ 3.76 | N/A |
| EPS | ★ 2.50 | N/A |
| Revenue | ★ $86,055,700.00 | N/A |
| Revenue This Year | $5.55 | N/A |
| Revenue Next Year | $6.03 | $45.45 |
| P/E Ratio | $156.07 | ★ N/A |
| Revenue Growth | ★ 5.86 | N/A |
| 52 Week Low | $351.03 | $11.00 |
| 52 Week High | $526.81 | $14.21 |
| Indicator | WINA | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 37.46 | 48.15 |
| Support Level | $368.70 | $11.25 |
| Resistance Level | $387.52 | $13.61 |
| Average True Range (ATR) | 21.98 | 0.95 |
| MACD | -4.62 | 0.00 |
| Stochastic Oscillator | 27.78 | 31.83 |
Winmark Corp is a franchisor of value-oriented retail store concepts that buy, sell, and trade gently used merchandise. The company has one reportable segment, including Franchising, and one non-reportable segment, Leasing. The franchising segment franchises value-oriented retail stores that buy, sell, trade, and consign merchandise as well as provide strategic consulting services relating to franchising. The leasing segment includes the middle-market equipment leasing business and small-ticket financing business. It generates a majority of its revenue from the Franchising segment.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.